IMO, January is a likely time for them to announce another candidate. To be honest, I have no idea why people are excited or even hot and bothered about another drug candidate. They have three major drugs in development right now, is that not enough to be excited about? Further, do you guys really expect a new drug candidate to be a major market moving event, or are people just bored to death talking about Ponatinb and Ridaforolimus? Relax, because in a few months you will have all you want to talk about 113.
News 
Market Data 
Discover 
AI
